BTG2: A rising star of tumor suppressors (Review)

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 459-464

  Mao, Bijing ^a   Zhang, Zhimin ^a,b   Wang, Ge ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

BTG2; Cancer; MiRNAs; Tumor suppressor

Indexed keywords

CYCLIN B1; CYCLIN D1; CYCLIN E; MICRORNA 21; PROTEIN P53; BTG2 PROTEIN, HUMAN; IMMEDIATE EARLY PROTEIN; MICRORNA; MIRN21 MICRORNA, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; B CELL TRANSLOCATION GENE 2 GENE; CANCER GENETICS; CANCER INHIBITION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; EARLY RESPONSE GENE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETIC REGULATION; HUMAN; MULTIGENE FAMILY; NEOPLASM; NONHUMAN; REVIEW; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; MICRORNAS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84918526501     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2765     Document Type: Review

References (61)

1. Zhang Z, Chen C, Wang G, Yang Z, San J, Zheng J, Li Q, Luo X, Hu Q, Li Z and Wang D: Aberrant expression of the p53-inducible antiproliferative gene BTG2 in hepatocellular carcinoma is associated with overexpression of the cell cycle-related proteins. Cell Biochem Biophys 61: 83-91, 2011.
2. Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Benard J, Douc-Rasy S and Cappellen D: p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res 36: 4222-4232, 2008.
3. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR and Gudkov AV: A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 20: 236-252, 2006.
4. Horiuchi M, Takeuchi K, Noda N, Muroya N, Suzuki T, Nakamura T, Kawamura-Tsuzuku J, Takahasi K, Yamamoto T and Inagaki F: Structural basis for the antiproliferative activity of the Tob-hCaf1 complex. J Biol Chem 284: 13244-13255, 2009.
5. Winkler GS: The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 222: 66-72, 2010.
6. Yang X, Morita M, Wang H, Suzuki T, Yang W, Luo Y, Zhao C, Yu Y, Bartlam M, Yamamoto T and Rao Z: Crystal structures of human BTG2 and mouse TIS21 involved in suppression of CAF1 deadenylase activity. Nucleic Acids Res 36: 6872-6881, 2008.
7. Duriez C, Moyret-Lalle C, Falette N, El-Ghissassi F and Puisieux A: BTG2, its family and its tutor. Bull Cancer 91: E242-E253, 2004.
8. Busson M, Carazo A, Seyer P, Grandemange S, Casas F, Pessemesse L, Rouault JP, Wrutniak-Cabello C and Cabello G: Coactivation of nuclear receptors and myogenic factors induces the major BTG1 influence on muscle differentiation. Oncogene 24: 1698-1710, 2005.
9. Ou YH, Chung PH, Hsu FF, Sun TP, Chang WY and Shieh SY: The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J 26: 3968-3980, 2007.
10. Buanne P, Corrente G, Micheli L, Palena A, Lavia P, Spadafora C, Lakshmana MK, Rinaldi A, Banfi S, Quarto M, Bulfone A and Tirone F: Cloning of PC3B, a novel member of the PC3/BTG/ TOB family of growth inhibitory genes, highly expressed in the olfactory epithelium. Genomics 68: 253-263, 2000.
11. Lim IK: TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol 132: 417-426, 2006.
12. Bradbury A, Possenti R, Shooter EM and Tirone F: Molecular cloning of PC3, a putatively secreted protein whose mRNA is induced by nerve growth factor and depolarization. Proc Natl Acad Sci USA 88: 3353-3357, 1991.
13. Fletcher BS, Lim RW, Varnum BC, Kujubu DA, Koski RA and Herschman HR: Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. J Biol Chem 266: 14511-14518, 1991.
14. Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C and Puisieux A: Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14: 482-486, 1996.
15. Melamed J, Kernizan S and Walden PD: Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell 34: 28-32, 2002.
16. Passeri D, Marcucci A, Rizzo G, Billi M, Panigada M, Leonardi L, Tirone F and Grignani F: Btg2 enhances retinoic acid-induced differentiation by modulating histone H4 methylation and acetylation. Mol Cell Biol 26: 5023-5032, 2006.
17. Konrad MA and Zuniga-Pflucker JC: The BTG/TOB family protein TIS21 regulates stage-specific proliferation of developing thymocytes. Eur J Immunol 35: 3030-3042, 2005.
18. Matsuda S, Rouault J, Magaud J and Berthet C: In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 497: 67-72, 2001.
19. Cho BO, Jeong YW, Kim SH, Park K, Lee JH, Kweon GR and Park JC: Up-regulation of the BTG2 gene in TPA- or RA-treated HL-60 cell lines. Oncol Rep 19: 633-637, 2008.
20. Zhang L, Huang H, Wu K, Wang M and Wu B: Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep 37: 2579-2586, 2010.
21. Ma XM and Ni KL: Expression of antiproliferation gene BTG2 in human pancreatic cancer and its antiproliferation effect. World J Tumor 9: 20-24, 2010 (In Chinese).
22. Wei S, Hao C, Li X, Zhao H, Chen J and Zhou Q: Effects of BTG2 on proliferation inhibition and anti-invasion in human lung cancer cells. Tumour Biol 33: 1223-1230, 2012.
23. Wagener N, Bulkescher J, Macher-Goeppinger S, Karapanagiotou- Schenkel I, Hatiboglu G, Abdel-Rahim M, Abol-Enein H, Ghoneim MA, Bastian PJ, Muller SC, Haferkamp A, Hohenfellner M, Hoppe-Seyler F and Hoppe-Seyler K: Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients. Br J Cancer 108: 973-982, 2013.
24. Zhang ZM, Wang G, Yang ZX, Shan JL, Chen C, Jin F, Xu W, Li Q, Luo XZ, Wang D and Li ZP: The expression of B-cell translocation gene 2 in diethylnitrosamine-induced primary hepatocellular carcinoma rat model. Chin J Hepatol 17: 107-111, 2009 (In Chinese).
25. Kis E, Szatmári T, Keszei M, Farkas R, Esik O, Lumniczky K, Falus A and Sáfrány G: Microarray analysis of radiation response genes in primary human fibroblasts. Int J Radiat Oncol Biol Phys 66: 1506-1514, 2006.
26. Chu TY, Yang JT, Huang TH and Liu HW: Crosstalk with cancerassociated fibroblasts increases the growth and radiation survival of cervical cancer cells. Radiat Res 181: 540-547, 2014.
27. Choi KS, Kim JY, Lim SK, Choi YW, Kim YH, Kang SY, Park TJ and Lim IK: TIS21(/BTG2/PC3) accelerates the repair of DNA double strand breaks by enhancing Mre11 methylation and blocking damage signal transfer to the Chk2(T68)-p53(S20) pathway. DNA Repair (Amst) 11: 965-975, 2012.
28. Zhang YJ, Wei L, Liu M, Li J, Zheng YQ, Gao Y and Li XR: BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumour Biol 34: 1605-1613, 2013.
29. Hong JW, Ryu MS and Lim IK: Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death. J Biol Chem 280: 21256-21263, 2005.
30. Farioli-Vecchioli S, Tanori M, Micheli L, Mancuso M, Leonardi L, Saran A, Ciotti MT, Ferretti E, Gulino A, Pazzaglia S and Tirone F: Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3. FASEB J 21: 2215-22125. 2007.
31. Imran M and Lim IK: Regulation of Btg2(/TIS21/PC3) expression via reactive oxygen species-protein kinase C-NF kappa;β pathway under stress conditions. Cell Signal 25: 2400-2412, 2013.
32. Lim IK, Lee MS, Ryu MS, Park TJ, Fujiki H, Eguchi H and Paik WK: Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin-dependent kinase 4 proteins due to overexpression of TIS21. Mol Carcinog 23: 25-35, 1998.
33. Lim SK, Choi YW, Lim IK and Park TJ: BTG2 suppresses cancer cell migration through inhibition of Src-FAK signaling by downregulation of reactive oxygen species generation in mitochondria. Clin Exp Metastasis 29: 901-913, 2012.
34. Chiang KC, Tsui KH, Chung LC, Yeh CN, Feng TH, Chen WT, Chang PL, Chiang HY and Juang HH: Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Sci Rep 4: 5511, 2014.
35. Quy LN, Choi YW, Kim YH, Chwae YJ, Park TJ and Lim IK: TIS21(/BTG2/PC3) inhibits interleukin-6 expression via downregulation of STAT3 pathway. Cell Signal 25: 2391- 2399, 2013.
36. Farioli-Vecchioli S, Saraulli D, Costanzi M, Leonardi L, Cinà I, Micheli L, Nutini M, Longone P, Oh SP, Cestari V and Tirone F: Impaired terminal differentiation of hippocampal granule neurons and defective contextual memory in PC3/Tis21 knockout mice. PLoS One 4: e8339, 2009.
37. Imran M, Park TJ and Lim IK: TIS21/BTG2/PC3 enhances downregulation of c-Myc during differentiation of HL-60 cells by activating Erk1/2 and inhibiting Akt in response to all-transretinoic acid. Eur J Cancer 48: 2474-2485, 2012.
38. Park TJ, Kim JY, Oh SP, Kang SY, Kim BW, Wang HJ, Song KY, Kim HC and Lim IK: TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop. Hepatology 47: 1533-1543, 2008.
39. Ryu MS, Lee MS, Hong JW, Hahn TR, Moon E and Lim IK: TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp Cell Res 299: 159-170, 2004.
40. Miyata S, Mori Y and Tohyama M: PRMT1 and Btg2 regulates neurite outgrowth of Neuro2a cells. Neurosci Lett 445: 162-165, 2008.
41. Del Puerto HL, Martins AS, Moro L, Milsted A, Alves F, Braz GF and Vasconcelos AC: Caspase-3/-8/-9, Bax and Bcl-2 expression in the cerebellum, lymph nodes and leukocytes of dogs naturally infected with canine distemper virus. Genet Mol Res 9: 151-161, 2010.
42. Hu X, Xing L, Jiao Y, Xu J, Wang X, Han A and Yu J: BTG2 overexpression increases the radiosensitivity of breast cancer cells in vitro and in vivo. Oncol Res 20: 457-465, 2013.
43. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
44. Taenzer A, Alix-Panabieres C, Wikman H and Pantel K: Circulating tumor-derived biomarkers in lung cancer. J Thorac Dis 4: 448-449, 2012.
45. Plaisance-Bonstaff K and Renne R: Viral miRNAs. Methods Mol Biol 721: 43-66, 2011.
46. Kato M and Slack FJ: MicroRNAs: small molecules with big roles - C. elegans to human cancer. Biol Cell 100: 71-81, 2008.
47. Liu J, Liu X, Cui F, Chen G, Guan Y and He J: The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer. Chin J Cancer Res 24: 346-352, 2012 (In Chinese).
48. Pass HI: Biomarkers and prognostic factors for mesothelioma. Ann Cardiothorac Surg 1: 449-456, 2012.
49. Coppola V, Musumeci M, Patrizii M, Cannistraci A, Addario A, Maugeri-Sacca M, Biffoni M, Francescangeli F, Cordenonsi M, Piccolo S, Memeo L, Pagliuca A, Muto G, Zeuner A, De Maria R and Bonci D: BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene 32: 1843-1853, 2013.
50. Niu J, Shi Y, Tan G, Yang CH, Fan M, Pfeffer LM and Wu ZH: DNA damage induces NF-kappaB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J Biol Chem 287: 21783-21795, 2012.
51. Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY and Yan M: microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep 27: 1019-1026, 2012.
52. Liu M, Wu H, Liu T, Li Y, Wang F, Wan H, Li X and Tang H: Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res 19: 828-837, 2009.
53. Yang CH, Yue J, Pfeffer SR, Handorf CR and Pfeffer LM: MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem 286: 39172-39178, 2011.
54. Sun Q, Hang M, Guo X, Shao W and Zeng G: Expression and significance of miRNA-21 and BTG2 in lung cancer. Tumour Biol 34: 4017-4026, 2013.
55. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J , Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TM, De Giorgio A, Pinho FG, Fulci V, Britton DJ, Ahmad R, Habib NA, Coombes RC, Harding V, Knösel T, Stebbing J and Jiao LR: MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology 146: 268-277.e18, 2014.
56. J alava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL and Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 31: 4460-4471, 2012.
57. Alvarez-Saavedra M, Antoun G, Yanagiya A, Oliva-Hernandez R, Cornejo-Palma D, Perez-Iratxeta C, Sonenberg N and Cheng HY: miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet 20: 731-751, 2011.
58. Li Q, Wang G and Zhang ZM: The relationship between microRNA-18 and BTG2 in the carcinogenesis of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 17: 42-45, 2009 (In Chinese).
59. Takahashi F, Chiba N, Tajima K, Hayashida T, Shimada T, Takahashi M, Moriyama H, Brachtel E, Edelman EJ, Ramaswamy S and Maheswaran S: Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30: 3084-3095, 2011.
60. Choi JA and Lim IK: TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells. J Cancer Res Clin Oncol 139: 1657-1665, 2013.
61. Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J and Moch H: Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res 64: 1632-1638, 2004.